v3.26.3
Note 8 - Accrued Expenses
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 8—Accrued Expenses:

 

Accrued expenses consisted of the following (in thousands):

 

 

 

September 30, 2026

 

 

December 31, 2025

 

Current:

 

 

 

 

 

 

 

 

Accrued royalties

 

$8,902

 

 

$15,858

 

Accrued CRO services

 

 

7,060

 

 

 

3,793

 

Accrued variable consideration

 

 

15,143

 

 

 

14,215

 

Accrued bonus

 

 

5,613

 

 

 

8,377

 

Accrued compensation

 

 

5,631

 

 

 

5,797

 

Accrued other clinical development

 

 

793

 

 

 

567

 

Accrued professional fees

 

 

809

 

 

 

132

 

Accrued legal fees

 

 

195

 

 

 

990

 

Accrued manufacturing costs

 

 

1,178

 

 

 

93

 

Other

 

 

219

 

 

 

209

 

Totals

 

$45,543

 

 

$50,031

 

 

Accrued variable consideration represents estimates of adjustments to product revenue, net for which reserves are established. Accrued royalties represent royalties incurred in connection with the Company’s license agreement with Pfizer. Accrued CRO services, accrued other clinical development expenses, and accrued legal fees represent the Company’s estimates of such costs and are recognized as incurred. Accrued compensation includes commissions and vacation.